{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["RNDO-564"],["RNDO-564","pembrolizumab"]],"indication":null,"name":"RNDO-564-001","nct_id":"NCT07218003","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rndo-564-001-nct07218003. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Single Agent Dose Level 1","label":"Single Agent Dose Level 1","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Level 2","label":"Single Agent Dose Level 2","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Level 3","label":"Single Agent Dose Level 3","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Level 4","label":"Single Agent Dose Level 4","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Level 5","label":"Single Agent Dose Level 5","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Level 6","label":"Single Agent Dose Level 6","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Level 7","label":"Single Agent Dose Level 7","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Level 8","label":"Single Agent Dose Level 8","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Level 9","label":"Single Agent Dose Level 9","type":"EXPERIMENTAL"},{"description":"Combination Dose Escalation- Dose Level 1","label":"Combination Dose Escalation- Dose Level 1","type":"EXPERIMENTAL"},{"description":"Combination Dose Escalation - Dose Level 2","label":"Combination Dose Escalation - Dose Level 2","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Optimization - Dose Level 1","label":"Single Agent Dose Optimization - Dose Level 1","type":"EXPERIMENTAL"},{"description":"Single Agent Dose Optimization - Dose Level 2","label":"Single Agent Dose Optimization - Dose Level 2","type":"EXPERIMENTAL"},{"description":"Combination Dose Optimization - Dose Level 1","label":"Combination Dose Optimization - Dose Level 1","type":"EXPERIMENTAL"},{"description":"Combination Dose Optimization - Dose Level 2","label":"Combination Dose Optimization- Dose Level 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-03-31","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer","Cervical Cancer","Head and Neck Squamous Cell Cancer","Triple Negative Breast Cancer (TNBC)","Urothelial Carcinoma Bladder","Gastroesophageal Junction (GEJ) Adenocarcinoma","Esophageal Squamous Cell Cancer","Gastric Cancer","Cancer","Solid Tumors (Phase 1)"],"enrollment":{"count":149,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"RNDO-564","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-11","lead_sponsor":"Rondo Therapeutics","official_title":"An Open-Label, Multicenter, Phase 1/1b Study of RNDO-564 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer and Other Solid Tumors Associated With Nectin-4 Expression","overall_status":"ENROLLING_BY_INVITATION","phases":["PHASE1"],"primary_completion_date":{"date":"2029-02-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"All Arms: - Proportion of participants with adverse events (including dose limiting toxicities) as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0","timeFrame":"From Day 1 to 90-days post last dose"},{"measure":"Dose Optimization Arms: • Identify one or more recommended Phase 2 doses (RP2D)","timeFrame":"From Day 1 up to 24 months"}],"references":[],"start_date":{"date":"2025-11-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","url":"https://clinicaltrials.gov/study/NCT07218003"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rndo-564-001-nct07218003"}